Prognostic impact of MYC/BCL2 coexpression in DLBCL. (A-B) OS (A) and PFS (B) of patients with DLBCL with MYC/BCL2 coexpression (MYC⁺BCL2⁺) in the training set. (C-D) OS of patients with MYC⁺ DLBCL in the presence (C) or absence (D) of BCL2 coexpression in the training set. (E-F) OS of patients with BCL2⁺ DLBCL in the presence (E) or absence (F) of MYC coexpression in the training set.